InflaRx shifts focus to lead drug, cuts costs by 30% to extend cash runway
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
GlideTech materials are available in several standard base resins and offer customization options for specific applications
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
Syrma Johari is a globally recognised medical device engineering and manufacturing organisation
Elanco expects Befrena to launch in the US in the first half of 2026
The study will run across 18 sites and enroll roughly 200 patients over 24 months
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
The cancellation underscores the regulator’s strict stance against misleading cosmetic claims
Subscribe To Our Newsletter & Stay Updated